Key facts
- This page summarizes Norman C. Selby's Form 4 filing for INFINITY PHARMACEUTICALS, INC..
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 16 Jun 2022, 20:37.
Norman C. Selby - 16 Jun 2022 Form 4 Insider Report for INFINITY PHARMACEUTICALS, INC.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 16 Jun 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 16 Jun 2022, 20:37:31 UTC
- Prior SEC filing
- 11 Jun 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/Seth A. Tasker as attorney-in-fact for Norman C. Selby
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Norman C. Selby filed Form 4 for INFINITY PHARMACEUTICALS, INC. on 16 Jun 2022.
Change
- Previous filing in this sequence was filed on 11 Jun 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
INFI
transaction
Derivative
Stock Option(right to buy)
Award
- Transaction value
- $0
- Shares
- +45,000
- Change %
- Price
- $0.000000
- Shares after
- 45,000
- Date
- 16 Jun 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 45,000
- Exercise price
- $0.6790
- Footnotes
- F1
INFI
transaction
Derivative
Stock Option(right to buy)
Award
- Transaction value
- $0
- Shares
- +10,000
- Change %
- Price
- $0.000000
- Shares after
- 10,000
- Date
- 16 Jun 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 10,000
- Exercise price
- $0.6790
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as a director of the issuer.
Footnote F2
The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as Lead Independent Director of the issuer's Board of Directors.
SEC remarks
Exhibit 24 - Limited Power of Attorney